A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Email
Print
Playlists: new england journal of medicine nejm melanoma edward sausville cancer treatment cancer
In this video, Edward A. Sausville, M.D., Ph.D., discusses the promise of a new targeted drug therapy for advanced melanoma in an editorial in the New England Journal of Medicine published online on June 4, 2012. A medical oncologist and pharmacologist, Dr. Sausville is a professor of medicine at the University of Maryland School of Medicine and associate director for clinical research at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.
In the editorial, Dr. Sausville comments on a study that found that a single daily dose of the drug trametinib decreased tumor progression by about three months in patients with melanoma whose tumor cells had a particular mutation in a gene known as BRAF, compared with patients who received chemotherapy. Patients also experienced improved overall survival, with a 14 percent greater chance of being alive after six months.
Click to Print
Print Preview
